By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- The Accelerated Cure Project for Multiple Sclerosis (ACP) announced a collaboration with the Regeneron Genetics Center (RGC), a wholly-owned subsidiary of Regeneron Pharmaceuticals, Inc., that will sequence the entire exome region of all DNA samples in the ACP biospecimen repository. The exome is the protein-coding region of the human genome, which represents under 2 percent of the genome, but contains a majority of the known inherited genetic variants associated with all diseases (see also Accelerated Cure Project for Multiple Sclerosis).
The RGC will use its fully-automated sample preparation and data processing, and cutting-edge cloud-based informatics to sequence the exomes in DNA samples from the ACP Repository, an open-access research resource for qualified investigators with biosamples from over 3,200 participants. Sample donors include people diagnosed with multiple sclerosis (MS), neuromyelitis optica (NMO), and other related diseases, as well as control participants. The data will subsequently be returned to ACP and eventually made available to all qualified investigators for further studies, which can take advantage of the detailed patient information that accompanies each sample. This includes medical, epidemiological and treatment data and neurologist documentation of diagnostic and monitoring tests.
Keywords for this news article include: Genetics, Neurology, DNA Research, Epidemiology, Neuroimmunology, Health and Medicine, CNS Demyelinating Autoimmune Disease, Demyelinating Diseases and Conditions, Immune System Diseases and Conditions, Accelerated Cure Project for Multiple Sclerosis, Autoimmune Diseases and Conditions of the Nervous System.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC
(c) 2018 NewsRx LLC, source Health Newsletters